Cookies on the JDRF website

Our website uses cookies to make your experience as great as possible. By continuing to use the website, we will assume that you agree to the use of cookies on the website. However, if you would like to change your cookie settings, please visit the website of The Information Commissioner's Office to find out how to control or delete cookies on your browser.

All news

Find out the latest news about JDRF's research and fundraising events.

Displaying clinical trials


Behind the headlines: An end to jabs?

In the letters pages of yesterday's Mirror newspaper, you may have seen a letter to Dr Miriam asking about a vaccine that can cure type 1.

Dr Miriam gave a great response explaining that although there is a vaccine in the early stages of clinical trials, a lot more trials need to be done to prove that it works before it can be made available to people with type 1.

In the trial Dr Miriam talked about, JDRF-funded researchers are trying to determine if a fragment of molecule from insulin producing beta cells called ‘proinsulin peptide’ could be used to retrain the immune system not to attack beta cells.

So far, the research team have conducted a small safety trial in people with type 1 diabetes to make sure the treatment is safe for use in humans. This trial showed that the treatment was safe and there were also signs that it may help stop the immune system attacking beta cells. If future trials show that it works well, this treatment may be able to prevent type 1 from progressing in people who have recently been diagnosed with the condition.

Professor Mark Peakman, who is leading the trial, said ‘We are very excited about the proinsulin peptide. Results from our first trials showed that the therapy was safe and we also saw promising signs that it may be effective in turning off the immune response that attacks beta cells. We are now recruiting for a larger study to test if the vaccine does turn the immune response in people with type 1 diabetes’.

If you are interested in finding out more about taking part in these, and other clinical trials, read more about current clinical trials.


Member of the Royal Family recognises JDRF research

We are delighted and excited to let you know that Her Royal Highness The Duchess of Cornwall will visit The Cambridge Wellcome Trust Clinical Research Facility at Addenbrooke’s Hospital in February to learn more about the work of JDRF. She will meet with researchers who are working to prevent type 1 diabetes and its complications, as well as speaking to children with type 1 who have been involved with clinical trials.

Her Royal Highness will be welcomed by HM Vice Lord-Lieutenant of Cambridgeshire, Mrs Jane Lewin Smith JP, before touring the facility with Karen Addington, Chief Executive at JDRF, and Professor David Dunger, of The University of Cambridge.

The Duchess of Cornwall will also meet with Dr Roman Hovorka and Dr Tim Tree to learn about their JDRF funded research.  Dr Hovorka is working to develop a Closed Loop Artificial Pancreas whilst Dr Tree will be discussing the Diabetes Genes, Autoimmunity and Prevention (DGAP) Project. 

This visit will be a chance for Her Royal Highness to decide how she might like to be associated with JDRF in the future. We are delighted to have this opportunity to meet with her as she only works with charities that she has personally selected, and look forward to telling you more about the visit at a later date.


New trial seeks REMOVAL of complications threat

The first patient has just been recruited to join a new, large-scale JDRF-funded clinical trial. This major international research project is seeking to reduce the risk of cardiovascular disease in people with type 1 diabetes.

The five-year, £4.25m trial, is being led by researchers at the Universities of Glasgow and Dundee. Known as REMOVAL (Reducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes), the trial will investigate the effects of a drug called metformin on people aged 40 and over who have type 1 diabetes.

People involved in the trial will be asked to continue their regular insulin treatment but will be asked to add a daily tablet to their treatment regimen. 
They will be given either metformin or a placebo.

Metformin has been used for 40 years in the treatment of type 2 diabetes. Although it works by preventing high blood glucose levels, evidence also exists that it can improve blood vessel function, reduce risk factors for cardiovascular disease, and improve the action of insulin on the liver, even for people without diabetes. Small clinical trials using metformin with people with type 1 have been conducted in the past, but the studies have been too small to draw any firm conclusions. The REMOVAL trial should be able to provide doctors with a definitive answer as to whether metformin can help people living with type 1.

Over three years, researchers will monitor the effect of the treatment on the participants’ glucose control, and monitor if there is an effect on their ‘intima media thickness’: a measure of cardiovascular health that can help to predict the likelihood of heart attacks or strokes. This is measured using a simple ultrasound scan of the neck.

Ten hospitals around the UK are participating in the trial, along with sites in Australia, Canada, Denmark and the Netherlands. The research team need to recruit 499 more people from around the world (about 250 from the UK) to get involved in the trial.

So if you have type 1, are over 40, and would like to help find out if adding a simple pill to type 1 treatment could help prevent cardiovascular complications of diabetes, why not find out if a hospital near you is involved in the study?


The artificial pancreas ventures out of the clinic!

JDRF-funded researchers working as part of the Artificial Pancreas Consortium at Montpellier University Hospital in France and at the Universities of Padova and Pavia in Italy ran experiments with two patients in parallel.

Both patients attained near-normal glucose levels after spending a night outside hospital while their diabetes was automatically managed by a prototype artificial pancreas system. The patients were each asked to test the system by eating a meal in a restaurant and then spending a night in a hotel, all while using the device.

Eight more patients enrolled in the trial will begin outpatient testing in the coming weeks in Montpellier, France and in Padova, Italy.

Rachel Connor, Head of Research Communication at JDRF commented ‘This is brilliant news for people with type 1. Testing this system outside the hospital for the first time is an important milestone in the journey toward making the system available to people with type 1 around the world.’


Getting teenagers involved in research

Here at JDRF we receive lots of enquiries from people interested in taking part in clinical trials. This is great news. All the valuable fundraising by our supporters would not be nearly as useful if there were not lots of willing volunteers to test new treatments, drugs and devices. 

We also know that trials of new treatments for teenagers are particularly important as it can be a really difficult time to maintain good glucose control,  due to changing hormones and lifestyles. However, teenagers can be a tricky group to pin down for clinical trials, which is where you may be able to help.

If you know someone between 10 and 16 years old with type 1 who might be interested in taking part in a trial, read on.

The Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT) is a clinical trial being led by Professor David Dunger, who is a Professor of Paediatrics at Addenbrooke’s Hospital at the University of Cambridge. The aim of the work is to prevent the progression of cardiovascular and renal complications in high-risk adolescents. 

Blood pressure and fat lowering drugs are frequently used in adults with Type 1 diabetes to reduce risk for future complications. They may also be of value during adolescence when HbAIc  levels may be less well controlled. We plan to find out whether these drugs have a role in the treatment of adolescents through a large trial involving nearly a thousand young people. 

These teenagers will take part in the project which will take place in the UK, Australia and Canada.  It will take five years to complete and is currently the only study of its kind. The trial is in its third year but more volunteers are still needed.

In an initial screening stage, volunteers will be asked to provide urine samples. Depending on the levels of protein these samples contain, they may then be invited to take part in the main study testing the effects of blood pressure and cholesterol lowering drugs. To make it even easier to take part, the young people involved in the trial will have study visits arranged to coincide with their routine clinic visits so far as possible, and may even have their routine diabetes care provided through a special AdDIT clinic, so that they do not have the inconvenience of two clinic visits. Others will be invited to take part in a comparison study which will not involve taking any study drugs but in which they will be closely followed up.

Screening is taking place in these regions of the UK:

Aylesbury and High Wycombe [email protected]
Birmingham [email protected]
Birmingham (Heartlands) [email protected]
Bristol [email protected]
Bolton [email protected]
Cambridge [email protected]
Ipswich [email protected]
Manchester [email protected]
[email protected]
Newcastle and 
[email protected]
[email protected]
Northampton [email protected]
Norwich [email protected]
Oxford [email protected]
Reading [email protected]

[email protected]

Wigan [email protected]
West Suffolk [email protected]

Or you can also email the coordinating centre: [email protected]

There is a list of other type 1 diabetes clinical trials on our website with contact details so you can get in touch directly if you are interested. There are also a number of diabetes clinical research organisationsand databases listed on our website who can help you find suitable trials. 


ADDRESS-2 study appeals to people newly diagnosed with type 1

ADDRESS-2, a new project launched today is inviting people who are newly diagnosed type 1 diabetes and their siblings to get involved with research studies in order to help researchers to understand the way the condition works.

Jointly funded by JDRF and Diabetes UK and supported by the NIHR Diabetes Research Network, ADDRESS-2 is a project to establish a group of people aged 5-60 who have been diagnosed with type 1 diabetes within the previous 26 weeks who would be happy to participate in research.

Participants will be interviewed to collect demographics, information about their health and the health of their family. They will be asked to give a blood sample if they wish, for auto-antibody analysis, blood sample storage, DNA extraction and storage and be willing to be contacted by their local project team about future type 1 diabetes research studies.

The project will then create a national database of people who can be approached about taking part in type 1 diabetes trials or other clinical research studies. Researchers will also be able to access the information, blood samples and DNA repository which is important for their studies.

How can I get involved?
People newly diagnosed with type 1 diabetes will be approached in their hospital diabetes clinic, given information about the project, and asked to participate. Contact with siblings will be made via liaison with the newly diagnosed participants, or where appropriate, their parents. Diabetologists and paediatricians have agreed to help find participants in 75 hospital diabetes clinics across England and Wales. If you are interested in finding out more about how to get involved you can visit


Help Diabeates campaign takes new approach to diabetes research

‘Help Diabeates’ is a new campaign organised by the Diabetes Research Network (DRN). Launching today, the campaign aims to encourage people with diabetes to give permission to be approached about taking part in clinical research studies.

The campaign is taking place over the next 18 months in three areas of England: the North West, the South West, and the North East area of London. 
The research that patients could take part in is approved by the National Institute for Health Research (NIHR) and aims to improve the treatment diabetes patients receive now and in the future.

Professor David Matthews, Co-Director of the Diabetes Research Network and Professor of Diabetes Medicine at The Oxford Centre for Diabetes said: “This is a refreshing approach to recruit patients to a ‘consent for approach’ database. It means that diabetes patients are agreeing to be contacted in the future if a study becomes available which might suit them. It also means that clinical trials can be set up much faster which is ideal for diabetes research.”

If you are interested in getting involved, you can text ‘research’ and your name to 81400 or visit their website. You would then be contacted by an NHS call centre to discuss how you might be able to help with research projects in the future. At this point individuals can decide if they want to be included on the ‘consent for approach’ database.

You can also follow updates on the campaign on Twitter @helpdiabeates.


Study suggests gluten does not cause type 1 diabetes

Avoiding feeding gluten to babies who are at high genetic risk of developing type 1 diabetes does not substantially reduce their chances of developing the condition, according to a study published in the journal Diabetes Care.

A total of 150 babies who had a close family member with type 1 diabetes, and specific high risk genes, were fed gluten for the first time either at six months or 12 months old. They were then monitored for three years by researchers who looked for telltale antibodies that often appear before the onset of type 1 diabetes.

When compared with a control group, who were not instructed to follow a particular diet, there was no statistical difference in the numbers of children who later went on to develop type 1 diabetes.

JDRF-funded researchers are continuing to investigate the possible causes of type 1 diabetes through the TEDDY study. This collaborative project is following approximately 7000 children from birth until they reach age 15. Researchers will take blood samples and keep records of the children’s health, diet and other life experiences. This should help shed light on the various triggers that cause type 1 diabetes.

You can read the full Diabetes Care paper here (subscription required). 

Read more about the TEDDY study.


JDRF and Amylin partner to explore if mixing human hormone with insulin could better treat type 1

Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals have today announced that they will be working together to fund a series of clinical studies testing the use of amylin in type 1 diabetes treatment. The research will establish whether mixing the drug pramlintide, a man-made version of the human hormone amylin, with insulin could improve blood glucose control in people with type 1 diabetes, compared to the use of insulin alone.

In a healthy pancreas, both insulin and amylin are produced and released by the same cells. The two hormones work together to help stabilise blood glucose levels. Insulin helps the body regulate production and storage of glucose, while amylin helps control the rate at which glucose enters the blood after meals.

Currently, patients who use pramlintide must separately administer their daily insulin therapy, either through injections or an insulin pump. Creating a mixture of the two drugs that still offers the benefits of both hormones, might better mimic the way a healthy pancreas works.

This is the second research partnership between JDRF and Amylin working to improve treatments for people with type 1 diabetes. The project is part of JDRF’s Industry Discovery and Development Partnership (IDDP) program aiming to accelerate research that will lead to better treatments and a cure for type 1 diabetes.

Eleanor Kennedy, Head of Research Communication at JDRF said, ‘ It will be interesting to see whether mixing pramlintide with insulin has the potential to help people with type 1 diabetes tighten their glucose control. We look forward to seeing the outcomes of the research resulting from this partnership.”